Sign in

NCT06860568Completed

The GA in HSI Study

Annotation of Geographic Atrophy in Hyperspectral Images Captured With the Optina-4C™

Source: ClinicalTrials.gov · Last updated 6 Mar 2025

Brief summary (registry, in English)

This study used a retrospective dataset collected by Optina under different study protocols. The target study population will include adults over the age of 50 years, with and without the presence of AMD.

Status (registry)
Completed
Study type
Observational
Enrollment
42 (actual)
First submitted
28 Feb 2025
Start date
24 Dec 2024
Primary completion date
18 Feb 2025
Lead sponsor
Optina Diagnostics Inc.
NCT number
NCT06860568

What you commit to

  • Study type: Observational
  • Participants enrolled: 42
  • From 24 Dec 2024 to the primary completion date, 18 Feb 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • No exclusion criteria.

Who the study is looking for

  • Participants may enter the study only if ALL the following inclusion criteria are present:
  • Study participants over the age of 50 years who consented to participate in Optina studies CIP-22-003, CIP-22-004, DOC100463, or RWD-24-011.
  • MHRC H5 Image Cube has been reviewed by an Optina Analyst and identified as aligned with the Target Population (see Section 5.2).
  • MHRC H5 Image Cube has a corresponding OCT image.

Age in the registry: 50 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Optina Diagnostics Inc
Coordinator of this site? Confirm its status		MontrealCanadaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.